AACR Annual Meeting | Conference

Undetectable METex14 Following Savolitinib Is Associated with Higher PFS, OS in NSCLC

April 11th 2021

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

Seribantumab Induces Tumor Regression in NRG1 Fusion+ GI Cancer Mouse Models

April 11th 2021

Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion–positive gastrointestinal cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion–driven cancers.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

April 11th 2021

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Selpercatinib Demonstrates Favorable Safety Profile in RET-Altered Advanced Solid Tumors

April 11th 2021

Selpercatinib demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects, manageable early onset toxicity, and low rates of treatment discontinuation, in patients with RET-altered advanced solid tumors.

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

April 11th 2021

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

Lifileucel Yields Durable Responses in Pretreated Advanced Melanoma

April 11th 2021

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor.

Adjuvant Nivolumab/Ipilimumab Falls Short of RFS End Point in Resected, Late-Stage Melanoma

April 10th 2021

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

Nivolumab/Ipilimumab Showcases Significant Antitumor Activity in Metastatic CRPC

April 10th 2021

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.

Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer

April 10th 2021

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Zenocutuzumab Demonstrates Efficacy in Blocking Growth of NRG1 Fusion–Driven Tumors

April 10th 2021

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

Trastuzumab Deruxtecan Shows Sensitivity in Various Levels of HER2-Expressing Gastric Cancer Cells

April 10th 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Dr. Yacoub on the Rationale For Parsaclisib After Suboptimal Response to Ruxolitinib in Myelofibrosis

April 10th 2021

Abdulraheem Yacoub, MD, discusses the rationale behind examining parsaclisib following suboptimal response to ruxolitinib in patients with myelofibrosis.

Dr. Le on the Safety of Twice-Daily Poziotinib in EGFR- or HER2 Exon 20–Positive NSCLC

April 10th 2021

Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

April 10th 2021

Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.

Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid Biopsies

April 10th 2021

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Copanlisib/Rituximab Improves PFS in Relapsed Indolent Non-Hodgkin Lymphoma

April 10th 2021

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Healthy Lifestyle May Reduce Likelihood of Lethal Prostate Cancer Among Those With High Genetic Risk

April 10th 2021

Maintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.

Germline Variants Associated With High Heritability and Poor Outcomes in Neuroblastoma

April 10th 2021

The presence of pathogenic or likely pathogenic germline variants in cancer predisposition genes, which were identified in approximately 1 in 5 patients with neuroblastoma and were mostly inherited, was shown to correlate with worse event-free survival and overall survival vs the absence of germline variants.

Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers

April 10th 2021

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.